Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses

被引:281
作者
Brunstrom, Mattias [1 ]
Carlberg, Bo [1 ]
机构
[1] Umea Univ, Dept Publ Hlth & Clin Med, Med, SE-90187 Umea, Sweden
来源
BMJ-BRITISH MEDICAL JOURNAL | 2016年 / 352卷
关键词
CONVERTING-ENZYME-INHIBITION; LEFT-VENTRICULAR DYSFUNCTION; CORONARY-ARTERY-DISEASE; CARDIOVASCULAR MORBIDITY; MICROVASCULAR OUTCOMES; MYOCARDIAL-INFARCTION; RANDOMIZED-TRIAL; RECURRENT STROKE; URINARY ALBUMIN; DOUBLE-BLIND;
D O I
10.1136/bmj.i717
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To assess the effect of antihypertensive treatment on mortality and cardiovascular morbidity in people with diabetes mellitus, at different blood pressure levels. DESIGN Systematic review and meta-analyses of randomised controlled trials. DATA SOURCES CENTRAL, Medline, Embase, and BIOSIS were searched using highly sensitive search strategies. When data required according to the protocol were missing but trials were potentially eligible, we contacted researchers, pharmaceutical companies, and authorities. ELIGIBILITY CRITERIA Randomised controlled trials including 100 or more people with diabetes mellitus, treated for 12 months or more, comparing any antihypertensive agent against placebo, two agents against one, or different blood pressure targets. RESULTS 49 trials, including 73 738 participants, were included in the meta-analyses. Most of the participants had type 2 diabetes. If baseline systolic blood pressure was greater than 150 mm Hg, antihypertensive treatment reduced the risk of all cause mortality (relative risk 0.89, 95% confidence interval 0.80 to 0.99), cardiovascular mortality (0.75, 0.57 to 0.99), myocardial infarction (0.74, 0.63 to 0.87), stroke (0.77, 0.65 to 0.91), and end stage renal disease (0.82, 0.71 to 0.94). If baseline systolic blood pressure was 140-150 mm Hg, additional treatment reduced the risk of all cause mortality (0.87, 0.78 to 0.98), myocardial infarction (0.84, 0.76 to 0.93), and heart failure (0.80, 0.66 to 0.97). If baseline systolic blood pressure was less than 140 mm Hg, however, further treatment increased the risk of cardiovascular mortality (1.15, 1.00 to 1.32), with a tendency towards an increased risk of all cause mortality (1.05, 0.95 to 1.16). Metaregression analyses showed a worse treatment effect with lower baseline systolic blood pressures for cardiovascular mortality (1.15, 1.03 to 1.29 for each 10 mm Hg lower systolic blood pressure) and myocardial infarction (1.12, 1.03 to 1.22 for each 10 mm Hg lower systolic blood pressure). Patterns were similar for attained systolic blood pressure. CONCLUSIONS Antihypertensive treatment reduces the risk of mortality and cardiovascular morbidity in people with diabetes mellitus and a systolic blood pressure more than 140 mm Hg. If systolic blood pressure is less than 140 mm Hg, however, further treatment is associated with an increased risk of cardiovascular death, with no observed benefit.
引用
收藏
页数:10
相关论文
共 80 条
  • [1] AMERY A, 1985, LANCET, V1, P1349
  • [2] Standards of Medical Care in Diabetes-2015: Summary of Revisions
    不详
    [J]. DIABETES CARE, 2015, 38 : S4 - S4
  • [3] [Anonymous], 1974, JAMA-J AM MED ASSOC, V229, P409
  • [4] [Anonymous], BMJ
  • [5] [Anonymous], CALCIUM ANTAGONISTS
  • [6] Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose Observations From Traditional and Bayesian Random-Effects Meta-Analyses of Randomized Trials
    Bangalore, Sripal
    Kumar, Sunil
    Lobach, Iryna
    Messerli, Franz H.
    [J]. CIRCULATION, 2011, 123 (24) : 2799 - +
  • [7] Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial
    Benavente, O. R.
    Coffey, C. S.
    Conwit, R.
    Hart, R. G.
    McClure, L. A.
    Pearce, L. A.
    Pergola, P. E.
    Szychowski, J. M.
    Benavente, O. R.
    Hart, R. G.
    Pergola, P. E.
    Palacio, S.
    Castro, I.
    Farias, A.
    Roldan, A.
    Kase, C.
    Gavras, I.
    Lau, H.
    Ogrodnik, M.
    Allen, N.
    Meissner, I.
    Graves, J.
    Herzig, D.
    Covalt, J.
    Meyer, B.
    Jackson, C.
    Gamble, P.
    Kelly, N.
    Warner, J.
    Bell, J.
    Demaerschalk, B.
    Hogan, M.
    Wochos, D.
    Wieser, J.
    Cleary, B.
    Wood, L.
    Hanna, J.
    Zipp, T.
    Bailey, S.
    Cook, D.
    Liskay, A.
    Simcox, D.
    Kappler, J.
    Anderson, D.
    Grimm, R.
    Brauer, D.
    Pettigrew, C.
    Vaishnov, A.
    Sawaya, P.
    Fowler, A.
    [J]. LANCET, 2013, 382 (9891) : 507 - 515
  • [8] Reductions in the risks of recurrent stroke in patients with and without diabetes: The PROGRESS trial
    Berthet, K
    Neal, BC
    Chalmers, JP
    Macmahon, SW
    Bousser, M
    Colman, SA
    Woodward, M
    [J]. BLOOD PRESSURE, 2004, 13 (01) : 7 - 13
  • [9] Braunwald E, 2004, NEW ENGL J MED, V351, P2058
  • [10] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    Brenner, BM
    Cooper, ME
    de Zeeuw, D
    Keane, WF
    Mitch, WE
    Parving, HH
    Remuzzi, G
    Snapinn, SM
    Zhang, ZX
    Shahinfar, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) : 861 - 869